Charanjit Kaur

TL;DR: A comprehensive review of recent findings of mechanisms and signaling pathways by which microglial cells are activated in CNS inflammatory diseases and various forms of potential therapeutic options to inhibit the microglia activation which amplifies the inflammation-related neuronal injury in neurodegenerative diseases are summarized.

TL;DR: Clinically, anti-VEGF therapy has been shown to improve vision in diabetic maculopathy and in neovascular ARMD, and the visual benefit appears to arise from the restoration of BRB integrity with a reduction of retinal oedema.

TL;DR: Melatonin’s efficacy in combating free radical damage in the brain suggests that it can be a valuable therapeutic agent in the treatment of cerebral edema following traumatic brain injury or stroke.

TL;DR: Hypoxia-ischemia induces the expression of hypoxia inducible factor-1α and its target genes such as vascular endothelial growth factor (VEGF) and nitric oxide synthase (NOS) which results in loss of retinal ganglion cells occurring in hypoxic-ischen conditions.

TL;DR: Activated microglia TLR4 presents as a potential therapeutic target for neonatal hypoxia brain injuries after its roles in neuroinflammation in neonatal rats following hypoxic injury are investigated.